Actuate Therapeutics Announces New Phase 1b Trial of Elra in Combination with Retifanlimab and mFOLFIRINOX for Advanced Pancreatic Cancer

Reuters

2025/08/25

Actuate <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces New Phase 1b Trial of Elra in Combination with Retifanlimab and mFOLFIRINOX for Advanced Pancreatic Cancer

Actuate Therapeutics Inc. has announced plans for a Phase 1b clinical trial to evaluate the combination of their drug elra with Incyte Corporation's PD-1 inhibitor retifanlimab and modified FOLFIRINOX (mFOLFIRINOX) as frontline therapy for advanced pancreatic adenocarcinoma. This study will be conducted in collaboration with UPMC Hillman Cancer Center and Incyte. The trial aims to explore synergistic opportunities for patients who have not yet received systemic therapy and to assess ways to optimize elraglusib's potential through a complementary multi-agent approach. Results from this trial have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1064578) on August 25, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2562824030"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562824030\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562824030?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-25 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562824030","market":"fut","top_or_hot":-1,"title":"Actuate Therapeutics Announces New Phase 1b Trial of Elra in Combination with Retifanlimab and mFOLFIRINOX for Advanced Pancreatic Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Actuate <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces New Phase 1b Trial of Elra in Combination with Retifanlimab and mFOLFIRINOX for Advanced Pancreatic Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ACTU\">Actuate Therapeutics Inc</a>. has announced plans for a Phase 1b clinical trial to evaluate the combination of their drug elra with Incyte Corporation's PD-1 inhibitor retifanlimab and modified FOLFIRINOX (mFOLFIRINOX) as frontline therapy for advanced pancreatic adenocarcinoma. This study will be conducted in collaboration with UPMC Hillman Cancer Center and Incyte. The trial aims to explore synergistic opportunities for patients who have not yet received systemic therapy and to assess ways to optimize elraglusib's potential through a complementary multi-agent approach. Results from this trial have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1064578) on August 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Actuate Therapeutics Announces New Phase 1b Trial of Elra in Combination with Retifanlimab and mFOLFIRINOX for Advanced Pancreatic Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nActuate Therapeutics Announces New Phase 1b Trial of Elra in Combination with Retifanlimab and mFOLFIRINOX for Advanced Pancreatic Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-25 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Actuate <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces New Phase 1b Trial of Elra in Combination with Retifanlimab and mFOLFIRINOX for Advanced Pancreatic Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ACTU\">Actuate Therapeutics Inc</a>. has announced plans for a Phase 1b clinical trial to evaluate the combination of their drug elra with Incyte Corporation's PD-1 inhibitor retifanlimab and modified FOLFIRINOX (mFOLFIRINOX) as frontline therapy for advanced pancreatic adenocarcinoma. This study will be conducted in collaboration with UPMC Hillman Cancer Center and Incyte. The trial aims to explore synergistic opportunities for patients who have not yet received systemic therapy and to assess ways to optimize elraglusib's potential through a complementary multi-agent approach. Results from this trial have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1064578) on August 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INCY","symbol_name":"因塞特医疗","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nNDL1s25yf:1","article_id":"2562824030","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562824030","pubTimestamp":1756130472,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Actuate Therapeutics Announces New Phase 1b Trial of Elra in Combination with Retifanlimab and mFOLFIRINOX for Advanced Pancreatic Cancer. Actuate Therapeutics Inc. has announced plans for a Phase 1b clinical trial to evaluate the combination of their drug elra with Incyte Corporation's PD-1 inhibitor retifanlimab and modified FOLFIRINOX  as frontline therapy for advanced pancreatic adenocarcinoma. This study will be conducted in collaboration with UPMC Hillman Cancer Center and Incyte. The trial aims to explore synergistic opportunities for patients who have not yet received systemic therapy and to assess ways to optimize elraglusib's potential through a complementary multi-agent approach. Results from this trial have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INCY":"因塞特医疗","BK4550":"红杉资本持仓","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4532":"文艺复兴科技持仓","BK4139":"生物科技","ACTU":"Actuate Therapeutics Inc"},"translate_title":"Actuate Therapeutics宣布Elra联合Retifanlimab和mFOLFIRINOX治疗晚期胰腺癌的新1b期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":0.9,"ACTU":0.9},"content_text":"Actuate Therapeutics Announces New Phase 1b Trial of Elra in Combination with Retifanlimab and mFOLFIRINOX for Advanced Pancreatic Cancer\n    \n\nActuate Therapeutics Inc. has announced plans for a Phase 1b clinical trial to evaluate the combination of their drug elra with Incyte Corporation's PD-1 inhibitor retifanlimab and modified FOLFIRINOX (mFOLFIRINOX) as frontline therapy for advanced pancreatic adenocarcinoma. This study will be conducted in collaboration with UPMC Hillman Cancer Center and Incyte. The trial aims to explore synergistic opportunities for patients who have not yet received systemic therapy and to assess ways to optimize elraglusib's potential through a complementary multi-agent approach. Results from this trial have not yet been presented.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1064578) on August 25, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}